CN112577764A - Method for evaluating pulmonary delivery efficiency of liquid mist aerosol - Google Patents
Method for evaluating pulmonary delivery efficiency of liquid mist aerosol Download PDFInfo
- Publication number
- CN112577764A CN112577764A CN202011291616.0A CN202011291616A CN112577764A CN 112577764 A CN112577764 A CN 112577764A CN 202011291616 A CN202011291616 A CN 202011291616A CN 112577764 A CN112577764 A CN 112577764A
- Authority
- CN
- China
- Prior art keywords
- volumetric flask
- respiratory tract
- upper respiratory
- liquid medicine
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 59
- 239000000443 aerosol Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000003595 mist Substances 0.000 title claims abstract description 23
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 45
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 43
- 238000001914 filtration Methods 0.000 claims abstract description 36
- 238000004140 cleaning Methods 0.000 claims abstract description 10
- 239000008263 liquid aerosol Substances 0.000 claims abstract description 8
- 239000008367 deionised water Substances 0.000 claims description 26
- 229910021641 deionized water Inorganic materials 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 150000002500 ions Chemical class 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000008021 deposition Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01M—TESTING STATIC OR DYNAMIC BALANCE OF MACHINES OR STRUCTURES; TESTING OF STRUCTURES OR APPARATUS, NOT OTHERWISE PROVIDED FOR
- G01M99/00—Subject matter not provided for in other groups of this subclass
- G01M99/005—Testing of complete machines, e.g. washing-machines or mobile phones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Sampling And Sample Adjustment (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method for evaluating the pulmonary delivery efficiency of liquid aerosol, which comprises the following steps: firstly, putting a medicament into an atomizer; then starting an atomizer to atomize the medicament to obtain liquid-mist aerosol; simultaneously, at the output end of the filtering unit, the liquid mist aerosol is sucked into the upper respiratory tract model and the filtering unit; after the atomizer runs for a set time, the atomizer is closed, and then the liquid mist aerosol is stopped being inhaled; taking down the upper respiratory tract model and the filtering unit and respectively cleaning the upper respiratory tract model and the filtering unit so as to collect the liquid medicine attached to the upper respiratory tract model into the first volumetric flask and collect the liquid medicine attached to the filtering unit into the second volumetric flask; measuring the concentration of any ion in the liquid medicine in the first volumetric flask and the concentration of the same ion in the liquid medicine in the second volumetric flask respectively; finally obtaining the mass m of the liquid medicine in the first volumetric flask1The mass m of the liquid medicine in the second volumetric flask2And delivery efficiency. Thus, the present invention can be used to determine different typesEfficiency of intrapulmonary delivery of atomizer liquid mist aerosol.
Description
Technical Field
The invention belongs to the technical field of biomedical engineering, and particularly relates to a method for evaluating pulmonary delivery efficiency of liquid aerosol.
Background
Particle pollutants are generally present in the atmospheric environment, in the breathing process of people, particles in the air inevitably flow into a breathing system along with the air, and chemical components in the deposited particles can cause stress reaction of human tissue cells, so that oxidative damage of tissues and organs is caused, and various biological effects are caused to harm human health, wherein the most direct harm is to induce respiratory diseases, such as chronic obstructive pulmonary disease, asthma, emphysema and the like. The aerosol inhalation therapy is an effective way to treat the above diseases because of the advantages of rapid onset of action, small required dosage, less adverse reaction, avoidance of first-pass effect, etc. In practical application, the atomizer is an aerosol generating device for atomization therapy which is most widely applied, and is divided into a compression type atomizer, an ultrasonic atomizer and a net type atomizer, and the generated aerosol is in a liquid mist form, and can be applied to old patients suffering from COPD and infants suffering from pneumonia and bronchitis.
However, the deposition amount of the particulate matters in the upper respiratory tract is usually determined by a weighing method in the existing research on the deposition of the particulate matters in the upper respiratory tract, but the deposited liquid-mist aerosol is not solid, and the deposition amount of the particulate matters cannot be measured by the weighing method. Therefore, how to measure the efficiency of delivering liquid aerosol into the lung and what kind of experimental apparatus is applied is a technical problem that needs to be solved urgently in the prior art.
Disclosure of Invention
The invention aims to provide a method for evaluating the pulmonary delivery efficiency of liquid mist aerosol. In order to achieve the purpose, the invention adopts the following technical scheme:
a method for evaluating the pulmonary delivery efficiency of liquid aerosol is based on a collection system, wherein the collection system comprises an upper respiratory tract model and a filtering unit which are sequentially communicated with an atomizer; the method comprises the following steps:
step 1: putting the liquid medicine into an atomizer;
step 2: starting an atomizer to atomize the medicament to obtain liquid-mist aerosol; simultaneously, at the output end of the filtering unit, the liquid mist aerosol is sucked into the upper respiratory tract model and the filtering unit;
and step 3: the atomizer is closed after running for a set time, and then liquid mist aerosol is stopped being inhaled;
and 4, step 4: taking down the upper respiratory tract model and the filtering unit and respectively cleaning the upper respiratory tract model and the filtering unit so as to collect the liquid medicine attached to the upper respiratory tract model into a first volumetric flask and collect the liquid medicine attached to the filtering unit into a second volumetric flask;
and 5: respectively sampling the first volumetric flask and the second volumetric flask, and respectively measuring any ion concentration of the liquid medicine in the first volumetric flask and the same ion concentration of the liquid medicine in the second volumetric flask by using ion concentration measuring equipment;
step 6: obtaining the mass m of the liquid medicine in the first volumetric flask according to the ion concentration in the first volumetric flask and the volume of the solution in the first volumetric flask1(ii) a Obtaining the mass m of the liquid medicine in the second volumetric flask according to the ion concentration in the second volumetric flask and the volume of the solution in the second volumetric flask2；
And 7: obtaining the efficiency of intrapulmonary delivery DE: DE = m2/( m1+ m2)×100%。
Preferably, in step 4, the step of washing the upper airway model comprises:
step 41: placing the upper respiratory tract model into a first deionized water container, and then sealing the first deionized water container;
step 42: putting the first deionized water container into an ultrasonic cleaning machine for cleaning;
step 43: after the ultrasonic cleaning machine operates for a set time, taking out the first deionized water container, and then taking out the upper respiratory tract model from the first deionized water container;
step 44: washing the upper respiratory tract model by using deionized water so as to collect the liquid medicine attached to the upper respiratory tract model into the solution in the first deionized water container;
step 45: transferring the solution in the first deionized water container to the first volumetric flask.
Preferably, the collection system further comprises a vacuum pump, the vacuum pump and the filter unit being connected by a connection pipe.
Preferably, a flow meter is provided on the connection pipe between the vacuum pump and the filter unit.
Preferably, the filter unit includes a bubble absorption tube and a second filter device which communicate with each other; the input end of the bubble absorption tube is communicated with the output end of the upper respiratory tract model; and the output end of the bubble absorption pipe is communicated with the input end of the second filtering device.
Preferably, the filtration unit further comprises a first filtration device; the output end of the second filtering device is communicated with the input end of the first filtering device.
Preferably, the filter unit comprises a first filter device.
Compared with the prior art, the invention has the advantages that:
(1) based on atomizer, upper respiratory tract model, filter unit and vacuum pump, inhale upper respiratory tract model and filter unit with liquid fog aerosol to measure the liquid fog aerosol liquid medicine of deposit in upper respiratory tract model and the filter unit respectively, deliver efficiency in the lung with obtaining this atomizer.
(2) The invention can provide an in-vitro measuring device for the delivery efficiency of various types of liquid mist aerosol in lungs and a using method thereof. Experimenters adopting the invention are expected to reveal the deposition rule and the influence factors of the liquid aerosol in the upper respiratory tract of the human body, and explore the method for improving the atomization efficiency and optimizing the treatment effect.
Drawings
FIG. 1 is a flow chart of a method for evaluating the efficiency of pulmonary delivery of a liquid aerosol according to a first embodiment of the present invention;
FIG. 2 is a block diagram of a collection system according to a first embodiment of the present invention;
fig. 3 is a structural diagram of a collection system according to a second embodiment of the present invention.
The device comprises an atomizer 1, an upper respiratory tract model 2, a first filtering device 3, a flowmeter 4, a vacuum pump 5, a connecting pipe 6, a bubble absorbing pipe 7 and a second filtering device 8.
Detailed Description
The present invention will now be described in more detail with reference to the accompanying schematic drawings, in which preferred embodiments of the invention are shown, it being understood that one skilled in the art may modify the invention herein described while still achieving the advantageous effects of the invention. Accordingly, the following description should be construed as broadly as possible to those skilled in the art and not as limiting the invention.
Example 1
In the embodiment, a collection system is provided, as shown in fig. 2, the collection system includes an upper respiratory tract model 2, a filtering unit, a flow meter 4 and a vacuum pump 5 which are sequentially communicated with an atomizer 1. The filter unit and the vacuum pump 5 are connected through a connecting pipe 6; the flow meter 4 is provided on the connection pipe 6.
In the present embodiment, the upper airway model 2 may be a real, personalized upper airway model 2, or a simplified, universal upper airway model 2.
In the present embodiment, the filtering unit is the first filtering device 3. The function of the filter unit is to trap all droplets escaping from the upper airway model 2.
In this embodiment, the flow meter 4 can adjust the gas flow rate as needed.
Based on the collection system, the embodiment further provides an evaluation method of the pulmonary delivery efficiency of the liquid aerosol, as shown in fig. 1, which includes steps 1 to 7. In this embodiment, the reagent is a NaCl solution, and chloride ions are selected as any ions in the reagents to be tested. The method comprises the following specific steps:
step 1: putting a proper amount of the required liquid medicine into the atomizer 1; communicating the atomizer 1 with a collection system; the joint is sealed by using the raw material belt and is additionally provided with the throat hoop, so that the whole gas circuit is ensured to have good gas tightness.
Step 2: the vacuum pump 5 is turned on and the flow meter 4 is adjusted to the desired flow rate. The air flow rate and the temperature and humidity in the laboratory were recorded.
Then starting the atomizer 1 to atomize the medicament to obtain a liquid-mist aerosol (aerosol in the form of liquid mist); and simultaneously, at the output end of the filtering unit, the liquid mist aerosol is sucked into the upper respiratory tract model 2 and the filtering unit.
Specifically, the input end of the vacuum pump 5 is communicated with the output end of the filtering unit, namely, under the suction action of the vacuum pump 5, the liquid mist aerosol enters the collecting system. Wherein the timer is started at the same time as the atomizer 1 is started.
And step 3: after the atomizer 1 is operated for a set time, the atomizer 1 is turned off first, and then the vacuum pump 5 is turned off to stop inhaling the liquid mist aerosol.
And 4, step 4: take off upper respiratory tract model 2 and filter unit to wash respectively, collect to the second volumetric flask to the liquid medicine that adheres on first volumetric flask, the filter unit with the liquid medicine that adheres on the upper respiratory tract model 2.
Wherein, the cleaning steps of the upper respiratory tract model 2 and the filtering unit are the same. Taking the step of cleaning the upper respiratory tract model 2 as an example, the method specifically comprises the following steps:
the upper airway model 2 was first placed in a first deionized water container, which was then sealed. Wherein, the first deionized water container means that the container is filled with deionized water.
And then putting the first deionized water container into an ultrasonic cleaning machine for cleaning. In step 42, the method further comprises inverting the upper airway model 2 at set time intervals. Preferably, the upper respiratory tract model 2 is turned and cleaned every 3 minutes, and the process is repeated for 3-4 times.
And then, after the ultrasonic cleaning machine operates for a set time, taking out the first deionized water container, then opening the first deionized water container, and taking out the upper respiratory tract model 2 from the first deionized water container.
And then, washing the upper respiratory tract model by using deionized water so as to collect the liquid medicine attached to the upper respiratory tract model into the solution in the first deionized water container.
And finally, transferring the solution in the first deionized water container into a first volumetric flask, and turning and shaking the first volumetric flask so that the two parts of solution obtained in the first volumetric flask in sequence are uniformly mixed.
And 5: the first volumetric flask and the second volumetric flask are sampled, and the ion chromatograph is used to measure the ion concentration of any one of the liquid medicines in the first volumetric flask and the ion concentration of the same one of the liquid medicines in the second volumetric flask.
Step 6: obtaining the mass m of the liquid medicine in the first volumetric flask according to the ion concentration in the first volumetric flask and the volume of the solution in the first volumetric flask1(ii) a Obtaining the mass m of the liquid medicine in the second volumetric flask according to the ion concentration in the second volumetric flask and the volume of the solution in the second volumetric flask2. I.e. the mass of the liquid medicine deposited in the upper respiratory tract model 2 is m1(ii) a The mass of the liquid medicine deposited in the filtering unit is m2。
Specifically, the concentration of the liquid medicine is obtained by converting the ion concentration in the first volumetric flask according to the chemical formula of the liquid medicine; finally obtaining the mass m of the liquid medicine in the first volumetric flask according to the volume of the solution in the first volumetric flask1。
In this embodiment, the mass of the liquid medicine is also the mass of the solute NaCl; the chemical formula of the liquid medicine is also the chemical formula of the solute NaCl.
And 7: obtaining the efficiency of intrapulmonary delivery DE: DE = m2/( m1+ m2)×100%。
Example 2
In the present embodiment, the filter unit includes a bubble absorption tube 7, a second filter device 8, and a first filter device 3, which are connected in this order; the input end of the bubble absorption tube 7 is communicated with the output end of the upper respiratory tract model 2; the output end of the bubble absorption pipe 7 is communicated with the input end of the second filtering device 8; the output end of the second filter device 8 is communicated with the input end of the first filter device 3.
In this embodiment, the second filter device 8 is a reject type filter.
The specific embodiment takes HL100A fish-jumping hand-held atomizer 1 as an example, and other types of atomizers 1 can be selected; the used medicament is NaCl solution, and chloride ions are selected as any ions in the medicament to be detected.
Specifically, the upper airway model 2 is customized by high-precision CNC, which is composed of two symmetrical parts.
A filter membrane is arranged in the first filter device 3, the aperture of the filter membrane is 0.1 micron, and the liquid mist aerosol escaping from the deslagging type filter can be completely captured.
The air flow rate in the system is adjusted by turning a knob below the rotameter.
The bottom of the ultrasonic cleaner is provided with a plurality of industrial-grade shaking heads, and NaCl particles and NaCl solution deposited on each part are cleaned by cavitation effect.
The ion chromatograph used an anion chromatographic column, and the eluent was 4.5mmol/L sodium carbonate and 1.4mmol/L sodium bicarbonate, and the flow rate of the eluent was 1.0 ml/min. The concentration of chloride ions in the cleaning liquid of each component can be accurately measured.
In this example, the evaluation method of the efficiency of pulmonary delivery of liquid mist aerosol was the same as that in example 1.
In this example, the quantity of NaCl deposited in the upper airway model 2 is n1(ii) a The mass of NaCl deposited in the bubble absorption tube 7 is n2(ii) a The sum of the mass of NaCl deposited in the second filter device 8 and in the first filter device 3 is n3。
In this example, the efficiency of intrapulmonary delivery DE: DE = n2+ n3/( n1+ n2+ n3)×100%。
The above description is only a preferred embodiment of the present invention, and does not limit the present invention in any way. It will be understood by those skilled in the art that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (7)
1. A method for evaluating the pulmonary delivery efficiency of liquid aerosol is based on a collection system, wherein the collection system comprises an upper respiratory tract model and a filtering unit which are sequentially communicated with an atomizer; the method is characterized by comprising the following steps:
step 1: putting the liquid medicine into an atomizer;
step 2: starting an atomizer to atomize the medicament to obtain liquid-mist aerosol; simultaneously, at the output end of the filtering unit, the liquid mist aerosol is sucked into the upper respiratory tract model and the filtering unit;
and step 3: the atomizer is closed after running for a set time, and then liquid mist aerosol is stopped being inhaled;
and 4, step 4: taking down the upper respiratory tract model and the filtering unit and respectively cleaning the upper respiratory tract model and the filtering unit so as to collect the liquid medicine attached to the upper respiratory tract model into a first volumetric flask and collect the liquid medicine attached to the filtering unit into a second volumetric flask;
and 5: respectively sampling the first volumetric flask and the second volumetric flask, and respectively measuring any ion concentration of the liquid medicine in the first volumetric flask and the same ion concentration of the liquid medicine in the second volumetric flask by using ion concentration measuring equipment;
step 6: obtaining the mass m of the liquid medicine in the first volumetric flask according to the ion concentration in the first volumetric flask and the volume of the solution in the first volumetric flask1(ii) a Obtaining the mass m of the liquid medicine in the second volumetric flask according to the ion concentration in the second volumetric flask and the volume of the solution in the second volumetric flask2；
And 7: obtaining the efficiency of intrapulmonary delivery DE: DE = m2/( m1+ m2)×100%。
2. The method of claim 1, wherein the step of cleaning the upper airway model in step 4 comprises:
step 41: placing the upper respiratory tract model into a first deionized water container, and then sealing the first deionized water container;
step 42: putting the first deionized water container into an ultrasonic cleaning machine for cleaning;
step 43: after the ultrasonic cleaning machine operates for a set time, taking out the first deionized water container, and then taking out the upper respiratory tract model from the first deionized water container;
step 44: washing the upper respiratory tract model by using deionized water so as to collect the liquid medicine attached to the upper respiratory tract model into the solution in the first deionized water container;
step 45: transferring the solution in the first deionized water container to the first volumetric flask.
3. The method of claim 1, wherein the collection system further comprises a vacuum pump, and the vacuum pump and the filter unit are connected via a connection tube.
4. The method of claim 3, wherein a flow meter is disposed on the connection pipe between the vacuum pump and the filter unit.
5. The method of claim 1, wherein the filter unit comprises a bubble absorption tube and a second filter device which are in communication with each other; the input end of the bubble absorption tube is communicated with the output end of the upper respiratory tract model; and the output end of the bubble absorption pipe is communicated with the input end of the second filtering device.
6. The method of claim 5, wherein the filter unit further comprises a first filter device; the output end of the second filtering device is communicated with the input end of the first filtering device.
7. The method of claim 1, wherein the filter unit comprises a first filter device.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011291616.0A CN112577764A (en) | 2020-11-18 | 2020-11-18 | Method for evaluating pulmonary delivery efficiency of liquid mist aerosol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011291616.0A CN112577764A (en) | 2020-11-18 | 2020-11-18 | Method for evaluating pulmonary delivery efficiency of liquid mist aerosol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112577764A true CN112577764A (en) | 2021-03-30 |
Family
ID=75122734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011291616.0A Pending CN112577764A (en) | 2020-11-18 | 2020-11-18 | Method for evaluating pulmonary delivery efficiency of liquid mist aerosol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112577764A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050066968A1 (en) * | 2000-08-01 | 2005-03-31 | Shofner Frederick M. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient |
| CN105982734A (en) * | 2015-01-27 | 2016-10-05 | 中国医学科学院生物医学工程研究所 | Authentic human body upper respiratory tract model flow field aerosol deposition measurement method and test device |
| CN107271337A (en) * | 2017-04-24 | 2017-10-20 | 中国人民解放军军事医学科学院卫生装备研究所 | A kind of human body alveolar aerosol deposition measurement experiment system |
| CN109141991A (en) * | 2018-09-30 | 2019-01-04 | 西北核技术研究所 | A kind of aerosol on-line period device, aerosol quantified system analysis and method |
| CN111077296A (en) * | 2019-12-31 | 2020-04-28 | 上海市食品药品检验所 | Aerosol supply and regulation system and application thereof in electronic cigarette liquid inhalation exposure safety evaluation |
-
2020
- 2020-11-18 CN CN202011291616.0A patent/CN112577764A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050066968A1 (en) * | 2000-08-01 | 2005-03-31 | Shofner Frederick M. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient |
| CN105982734A (en) * | 2015-01-27 | 2016-10-05 | 中国医学科学院生物医学工程研究所 | Authentic human body upper respiratory tract model flow field aerosol deposition measurement method and test device |
| CN107271337A (en) * | 2017-04-24 | 2017-10-20 | 中国人民解放军军事医学科学院卫生装备研究所 | A kind of human body alveolar aerosol deposition measurement experiment system |
| CN109141991A (en) * | 2018-09-30 | 2019-01-04 | 西北核技术研究所 | A kind of aerosol on-line period device, aerosol quantified system analysis and method |
| CN111077296A (en) * | 2019-12-31 | 2020-04-28 | 上海市食品药品检验所 | Aerosol supply and regulation system and application thereof in electronic cigarette liquid inhalation exposure safety evaluation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1689476B1 (en) | Medical device for reducing the carbon-dioxide content in a volume | |
| US4094317A (en) | Nebulization system | |
| EP1292225B1 (en) | Apparatus for collection of airway gases | |
| JP2003504092A (en) | Pulmonary medication system and method | |
| CN205391423U (en) | Portable internal medicine ultrasonic atomization inhaler | |
| CA2861520A1 (en) | Method of neutralizing an aerosol containing a compound of interest dissolved in a low ph solution | |
| CN111207964A (en) | Respiratory tract secretion sampling mask | |
| CN208447842U (en) | A kind of breath exposure device and breath exposure system for respiratory administration | |
| CN106823079A (en) | A kind of quantitative atomized medicine introducing device of delivery type | |
| CN105982734A (en) | Authentic human body upper respiratory tract model flow field aerosol deposition measurement method and test device | |
| JP2009533681A (en) | Diagnostic device for measuring particle formation | |
| Barry et al. | Drug output from nebulizers is dependent on the method of measurement | |
| CN107029324A (en) | A kind of ultrasound medical atomizer | |
| CN204840546U (en) | Portable ultrasonic atomization ware that is used for internal medicine | |
| CN112577764A (en) | Method for evaluating pulmonary delivery efficiency of liquid mist aerosol | |
| US11475798B2 (en) | Simulation device for characterizing aerodynamics of dry power inhalants in respiratory system | |
| JPH0678997A (en) | Method for generating particle reaching alveoli, and treatment equipment using it | |
| CN219148837U (en) | Instant atomizing and instant inhalation type atomizing drug delivery device | |
| CN217745180U (en) | Human body lung-heat clearing equipment | |
| CN211825264U (en) | Respiratory tract secretion sampling mask | |
| CN211373993U (en) | Test equipment for improving in-vivo and in-vitro correlation of inhalation preparation | |
| CN113466455A (en) | Automatic processing device for virus screening in sputum collection | |
| CN209421920U (en) | Main stream-type End-tidal carbon dioxide detection device | |
| CN106267496A (en) | With inhaling oxygen-supplying type joint oxygen device | |
| CN220530462U (en) | Atomization drug administration simulation device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |